Paper39875975
CXCR4 promotes tumor stemness maintenance and CDK4/6 inhibitors resistance in ER-positive breast cancer.
Shi Q and 4 others. Breast Cancer Res, 2025. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. CXCR4 promotes tumor stemness maintenance and CDK4/6 inhibitors resistance in ER-positive breast cancer. Papers, record 39875975. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39875975
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- CXCR4 promotes tumor stemness maintenance and CDK4/6 inhibitors resistance in ER-positive breast cancer.
- PubMed
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Receptors, CXCR4 | Major topic |
| Breast Neoplasms | Major topic |
| Drug Resistance, Neoplasm | Major topic |
| Neoplastic Stem Cells | Major topic |
| Protein Kinase Inhibitors | Major topic |
| Humans | |
| Female | |
| Animals | |
| Cyclin-Dependent Kinase 6 | |
| Cyclin-Dependent Kinase 4 | |
| Mice | |
| Xenograft Model Antitumor Assays | |
| Pyridines | |
| Cell Line, Tumor | |
| Receptors, Estrogen | |
| Gene Expression Regulation, Neoplastic | |
| Piperazines | |
| beta Catenin | |
| Cell Proliferation |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 2023A1515010127 | the Natural Science Foundation of Guangdong | PubMed |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Erratum in | 40001186 | Correction: CXCR4 promotes tumor stemness maintenance and CDK4/6 inhibitors resistance in ER-positive breast cancer. | https://conductscience.org/library/papers/40001186 |
Source PubMed
References39
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29117498 | 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. | N Engl J Med | 2017 | https://conductscience.org/library/papers/29117498 | PubMed |
| 2 | 9694791 | The regulation of E2F by pRB-family proteins. | Genes Dev | 1998 | https://conductscience.org/library/papers/9694791 | PubMed |
| 3 | 18467589 | Phosphorylation of retinoblastoma protein by viral protein with cyclin-dependent kinase function. | Science | 2008 | https://conductscience.org/library/papers/18467589 | PubMed |
| 4 | 22475046 | Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. | Breast Cancer Res | 2012 | https://conductscience.org/library/papers/22475046 | PubMed |
| 5 | 15138475 | Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. | Br J Cancer | 2004 | https://conductscience.org/library/papers/15138475 | PubMed |
| 6 | 28303264 | The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies. | Trends Cancer | 2017 | https://conductscience.org/library/papers/28303264 | PubMed |
| 7 | 30345905 | Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. | N Engl J Med | 2018 | https://conductscience.org/library/papers/30345905 | PubMed |
| 8 | 31563959 | The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. | JAMA Oncol | 2020 | https://conductscience.org/library/papers/31563959 | PubMed |
| 9 | 33761995 | Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice. | Breast Cancer Res | 2021 | https://conductscience.org/library/papers/33761995 | PubMed |
| 10 | 35263519 | Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. | N Engl J Med | 2022 | https://conductscience.org/library/papers/35263519 | PubMed |
| 11 | 27959613 | Palbociclib and Letrozole in Advanced Breast Cancer. | N Engl J Med | 2016 | https://conductscience.org/library/papers/27959613 | PubMed |
| 12 | 30914635 | Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. | Nat Commun | 2019 | https://conductscience.org/library/papers/30914635 | PubMed |
| 13 | 27748766 | Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence. | Oncogene | 2017 | https://conductscience.org/library/papers/27748766 | PubMed |
| 14 | 31594766 | PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer. | Cancer Discov | 2020 | https://conductscience.org/library/papers/31594766 | PubMed |
| 15 | 30554963 | Phenotypic Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance. | Cell Stem Cell | 2019 | https://conductscience.org/library/papers/30554963 | PubMed |
| 16 | 36127291 | PFKFB4 facilitates palbociclib resistance in oestrogen receptor-positive breast cancer by enhancing stemness. | Cell Prolif | 2023 | https://conductscience.org/library/papers/36127291 | PubMed |
| 17 | 30029203 | Cancer stem cell in breast cancer therapeutic resistance. | Cancer Treat Rev | 2018 | https://conductscience.org/library/papers/30029203 | PubMed |
| 18 | 35301432 | A novel HIF-2α targeted inhibitor suppresses hypoxia-induced breast cancer stemness via SOD2-mtROS-PDI/GPR78-UPRER axis. | Cell Death Differ | 2022 | https://conductscience.org/library/papers/35301432 | PubMed |
| 19 | 30228301 | Stem cell fate in cancer growth, progression and therapy resistance. | Nat Rev Cancer | 2018 | https://conductscience.org/library/papers/30228301 | PubMed |
| 20 | 26390243 | Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. | Nat Med | 2015 | https://conductscience.org/library/papers/26390243 | PubMed |
Cited by9
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42780585 | Changes in the metabolism of axillary lymph node cells as a predictor of regional metastasis in breast cancer. | World J Exp Med | 2026 | https://conductscience.org/library/papers/42780585 | PubMed |
| 42768738 | Cancer Stem Cell Quiescence: Molecular and Microenvironmental Evidence for an Actively Regulated Adaptive Survival Strategy. | Cancer Med | 2026 | https://conductscience.org/library/papers/42768738 | PubMed |
| 42512259 | CDK4/6 Inhibitor-Induced Senescence in Cancer: Mechanisms and Therapeutic Implications. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42512259 | PubMed |
| 41997307 | Regulation of PSAT1 and PHGDH by m6A in endocrine-resistant breast cancer cells. | Biochim Biophys Acta Mol Basis Dis | 2026 | https://conductscience.org/library/papers/41997307 | PubMed |
| 41210649 | Could circulating tumor cells explain why breast conservation improves survival despite higher locoregional recurrence? | Transl Breast Cancer Res | 2025 | https://conductscience.org/library/papers/41210649 | PubMed |
| 40944804 | Tumor microenvironment response to neoadjuvant therapy in breast cancer: insights from single-cell and spatial omics. | Med Oncol | 2025 | https://conductscience.org/library/papers/40944804 | PubMed |
| 40755423 | Emerging Mechanisms of Therapy Resistance in Metastatic ER+ Breast Cancer. | Endocrinology | 2025 | https://conductscience.org/library/papers/40755423 | PubMed |
| 40559213 | Natural Compounds That Target Glioma Stem Cells. | NeuroSci | 2025 | https://conductscience.org/library/papers/40559213 | PubMed |
| 40362664 | Mercury Bioaccumulation in Female Breast Cancer Is Associated to CXCR4 Expression. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40362664 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CXCR4 | 7852 | PubTator's text mining | https://conductscience.org/library/genes/7852 | NCBI Gene |
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| WNT5A | 7474 | PubTator's text mining | https://conductscience.org/library/genes/7474 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39875975
GET https://conductscience.org/api/papers/v1/39875975/references?page=2